Although the majority (88%) of patients with breast cancer are initially diagnosed with hormone receptor (Hr)-positive and/or human epidermal growth factor receptor 2 (HER2)-positive disease [11, 12], receptor status discordance from breast cancer diagnosis through relapses and disease progression occurs frequently, most commonly involving changes in Hr status [13–17]. Here, HR is linked to breast carcinoma.